Ignalis-M 100/500 Tablet ER is a combination oral antidiabetic medication containing Sitagliptin 100 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone or those already receiving monotherapy with either component. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from alpha cells in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Ignalis-M 100/500 Tablet ER should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular assessment of renal function is recommended before and during therapy. This combination provides complementary mechanisms to achieve better glycemic control with a favorable safety profile.